"The U.S. Food and Drug Administration will complete its phase-out of all inhaler medical products containing chlorofluorocarbons (CFCs) by Dec. 31, 2013. This effort is to comply with an international treaty to protect the ozone layer by phasing "...
Maxair Side Effects Center
Medical Editor: John P. Cunha, DO, FACOEP
Maxair (pirbuterol) inhalation is used to treat conditions such as asthma, bronchitis, and emphysema. It is a bronchodilator. Common side effects include headache, dizziness, lightheadedness, insomnia, tremor or nervousness, sweating, nausea, vomiting, or diarrhea, or dry mouth.
The usual dose of Maxair for adults and children 12 years and older is two inhalations (400 mcg) repeated every 4-6 hours. One inhalation (200 mcg) repeated every 4-6 hours may be sufficient for some patients. A total daily dose of 12 inhalations should not be exceeded. Maxair may interact with beta-blockers, tricyclic antidepressants, monoamine oxidase (MAO) inhibitors, other inhaled bronchodilators, caffeine, diet pills, or decongestants. Tell your doctor all medications you use. During pregnancy, Maxair should be used only if prescribed. It is unknown if this drug passes into breast milk. Consult your doctor before breast-feeding.
Our Maxair (pirbuterol) Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
What is Patient Information in Detail?
Easy-to-read and understand detailed drug information and pill images for the patient or caregiver from Cerner Multum.
Maxair in Detail - Patient Information: Side Effects
Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficult breathing; swelling of your face, lips, tongue, or throat.
Call your doctor at once if you have a serious side effect such as:
- bronchospasm (wheezing, chest tightness, trouble breathing), especially after starting a new canister of this medicine;
- chest pain and fast, pounding, or uneven heart beats;
- tremor, nervousness;
- low potassium (confusion, uneven heart rate, extreme thirst, increased urination, leg discomfort, muscle weakness or limp feeling); or
- dangerously high blood pressure (severe headache, blurred vision, buzzing in your ears, anxiety, confusion, chest pain, shortness of breath, uneven heartbeats, seizure).
Less serious side effects may include:
- headache, dizziness;
- sleep problems (insomnia);
- cough, hoarseness, sore throat, runny or stuffy nose;
- mild nausea, vomiting;
- dry mouth and throat;
- muscle pain; or
Read the entire detailed patient monograph for Maxair (Pirbuterol) »
What is Prescribing information?
The FDA package insert formatted in easy-to-find categories for health professionals and clinicians.
Maxair FDA Prescribing Information: Side Effects
The following rates of adverse reactions to pirbuterol are based on single- and multiple-dose clinical trials involving 761 patients, 400 of whom received multiple doses (mean duration of treatment was 2.5 months and maximum was 19 months).
The following were the adverse reactions reported more frequently than 1 in 100 patients:
CNS: nervousness (6.9%), tremor (6.0%), headache (2.0%), dizziness (1.2%).
Respiratory: cough (1.2%).
Gastrointestinal: nausea (1.7%).
The following adverse reactions occurred less frequently than 1 in 100 patients and there may be a causal relationship with pirbuterol:
Ear, Nose and Throat: smell/taste changes, sore throat.
Other adverse reactions were reported with a frequency of less than 1 in 100 patients but a causal relationship between pirbuterol and the reaction could not be determined: migraine, productive cough, wheezing, and dermatitis.
The following rates of adverse reactions during three-month controlled clinical trials involving 310 patients are noted. The table does not include mild reactions.
PERCENT OF PATIENTS WITH MODERATE TO SEVERE ADVERSE REACTIONS
|Central Nervous System|
Electrocardiograms: Electrocardiograms, obtained during a randomized, double-blind, crossover study in 57 patients, showed no observations or findings considered clinically significant, or related to drug administration. Most electrocardiographic observations, obtained during a randomized, double-blind, cross-over study in 40 patients, were judged not clinically significant or related to drug administration. One patient was noted to have some changes on the one hour postdose electrocardiogram consisting of ST and T wave abnormality suggesting possible inferior ischemia. This abnormality was not observed on the predose or the six hours postdose ECG. A treadmill was subsequently performed and all the findings were normal.
Read the entire FDA prescribing information for Maxair (Pirbuterol) »
Additional Maxair Information
Report Problems to the Food and Drug Administration
Allergies & Asthma
Improve treatments & prevent attacks.